The Food and Drug Administration (FDA) and The Critical Path Institute (C-Path) today announced the formation of the Predictive Safety Testing Consortium between C-Path and five of America’s largest pharmaceutical companies to share internally developed laboratory methods to predict the safety of new treatments before they are tested in humans.
